Centene Corporation: Q1 2026 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Centene Corporation for the period ended March 31, 2026. Centene is a leading healthcare enterprise providing managed care services to government-sponsored (Medicaid, Medicare) and commercial programs. As of March 31, 2026, the company reported total managed care membership of 26.3 million, a decrease of 1.7 million (6%) year-over-year, primarily driven by Medicaid eligibility redeterminations and Marketplace regulatory changes.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Total Revenues | $49.94 billion | $46.62 billion | +7% |
| Premium & Service Revenues | $44.66 billion | $42.49 billion | +5% |
| Net Earnings (GAAP) | $1.54 billion | $1.31 billion | +18% |
| Diluted EPS (GAAP) | $3.11 | $2.63 | +18% |
| Adjusted Diluted EPS | $3.37 | $2.90 | +16% |
| Operating Cash Flow | $4.37 billion | $1.51 billion | +189% |
| Health Benefits Ratio (HBR) | 87.3% | 87.5% | -20 bps |
| SG&A Expense Ratio | 7.6% | 7.9% | -30 bps |
| Total Debt | $16.37 billion | $17.40 billion | -6% |
| Cash & Equivalents | $21.26 billion | $17.89 billion | +19% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 7% year-over-year, driven by premium yield growth in the Prescription Drug Plan (PDP) business, state-directed payments, and rate increases in Medicaid to address medical trends. This growth occurred despite a 6% decline in total membership.
- Profitability: Net earnings rose 18% to $1.54 billion. The improvement was aided by a $270 million premium deficiency reserve recorded in Q1 2025 for Medicare Advantage, which was not repeated in Q1 2026 as the business progressed toward profitability.
- Segment Performance:
- Medicaid: Revenues up 9% and gross margin up 13%, driven by rate increases and cost management, offset by membership declines from eligibility redeterminations.
- Medicare: Revenues up 18% and gross margin up 29%, primarily due to PDP growth and the absence of the prior year's premium deficiency reserve.
- Commercial: Revenues down 6% and gross margin down 7%, reflecting reduced Marketplace membership due to the expiration of Enhanced Advance Premium Tax Credits (eAPTCs) and new regulatory rules.
- Debt Reduction: The company repurchased $1.03 billion of its 2027 Senior Notes, resulting in a $5 million pre-tax loss on debt extinguishment. Total debt decreased to $16.37 billion.
Guidance, Outlook, and Risks
- Regulatory Environment: The "One Big Beautiful Bill Act" (OBBBA) passed in July 2025 introduces work requirements and more frequent eligibility redeterminations for Medicaid, potentially increasing population morbidity starting in 2027. In the Marketplace, the expiration of eAPTCs and new integrity rules are expected to continue reducing membership and increasing morbidity.
- Medicare Part D: The Inflation Reduction Act (IRA) changes continue to impact Part D costs. CMS eliminated narrowed risk corridors for 2026, shifting plans back to standard risk-sharing, though a new Drug Subsidy was introduced to offset the loss of the Manufacturer Discount Program.
- Legal Proceedings: The company is defending against a federal securities class action and related derivative lawsuits filed in 2025 and 2026 alleging false statements regarding 2025 earnings guidance. Management denies wrongdoing but notes potential material adverse impacts if outcomes are unfavorable.
- Divestiture: Centene signed a definitive agreement in December 2025 to sell the remaining Magellan Health businesses. Assets and liabilities are classified as held for sale.
- Liquidity: The company maintains a strong liquidity position with $21.3 billion in cash and restricted cash. It expects available cash and operating cash flows to be sufficient for operations for at least 12 months.
Investor Verification Checklist
- Membership Trends: Verify the sustainability of the 6% membership decline and the specific impact of OBBBA work requirements on future Medicaid enrollment.
- Medical Cost Trends: Assess the company's ability to maintain the improved Health Benefits Ratio (87.3%) amidst rising pharmaceutical costs and increased utilization.
- Legal Exposure: Monitor the status of the federal securities class action and derivative lawsuits regarding 2025 earnings guidance.
- Receivable Sales: Review the terms and frequency of the sale of CMS Part D risk-sharing receivables, which generated $970 million in proceeds but a $30 million loss in Q1 2026.
- Contract Protests: Track the outcome of ongoing Medicaid procurement protests in Georgia and Texas, which could impact future revenue streams.